Osteoarthritis (OA) is a progressive degenerative disease of synovial joints, characterized by maladaptive pain during rest and joint use, lameness, destruction of articular cartilage and bony remodelling. OA is generally secondary to congenital and developmental abnormalities (elbow incongruety and dysplasia, osteochondritis dissecans, hip dysplasia); joint trauma such as fractures or ligamentous injuries; inflammation such as infections or immune-mediated diseases; neuropathic, neoplastic or iatrogenic causes. OA affects all the component of the joint including cartilage, subchondral bone, synovial membrane, synovial fluid, ligaments and tendons as well as periarticular soft tissue. Treatment for OA pain is effectively limited to the available products. The number of them proved to provide safe and effective treatment does not change rapidly. The approved pharmaceutic analgesic agent are the most reviewed products. The decision of when and how to treat OA is often based on a combination factors such as efficacy, product availability, cost, personal experiences, easy to administration and success or failure of previous treatments.

Analgesic Management of Chronic Osteoarthritic Pain

BUFALARI, Antonello;
2010

Abstract

Osteoarthritis (OA) is a progressive degenerative disease of synovial joints, characterized by maladaptive pain during rest and joint use, lameness, destruction of articular cartilage and bony remodelling. OA is generally secondary to congenital and developmental abnormalities (elbow incongruety and dysplasia, osteochondritis dissecans, hip dysplasia); joint trauma such as fractures or ligamentous injuries; inflammation such as infections or immune-mediated diseases; neuropathic, neoplastic or iatrogenic causes. OA affects all the component of the joint including cartilage, subchondral bone, synovial membrane, synovial fluid, ligaments and tendons as well as periarticular soft tissue. Treatment for OA pain is effectively limited to the available products. The number of them proved to provide safe and effective treatment does not change rapidly. The approved pharmaceutic analgesic agent are the most reviewed products. The decision of when and how to treat OA is often based on a combination factors such as efficacy, product availability, cost, personal experiences, easy to administration and success or failure of previous treatments.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/140223
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact